{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T03:49:41Z","timestamp":1752551381802,"version":"3.40.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011104","name":"Universitat Aut\u00f2noma de Barcelona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011104","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>This scoping review aims to deepen the understanding of end-of-life anticancer drug use in lung cancer patients, a disease marked by high mortality and symptom burden. Insight into unique end-of-life treatment patterns is crucial for improving the appropriateness of cancer care for these patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Comprehensive searches were carried out in Medline and Embase to find articles on the utilization of anticancer drugs in the end of life of lung cancer patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We identified 68 publications, highlighting the methodological characteristics of studies including the timing of the research, disease condition, treatment regimen, type of treatment, and features of the treatment. We outlined the frequency of anticancer drug use throughout different end-of-life periods.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This review provides a comprehensive overview of primary studies exploring end-of-life treatments in lung cancer patients. Methodological inconsistencies pose many challenges, revealing a notable proportion of patients experiencing potential overtreatment, warranting more standardized research methods for robust evaluations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12094-024-03711-1","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T15:01:32Z","timestamp":1728140492000},"page":"1980-1993","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Scoping review of anticancer drug utilization in lung cancer patients at the end of life"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7812-9600","authenticated-orcid":false,"given":"Endre","family":"Szigethy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4019-6290","authenticated-orcid":false,"given":"Mohammed","family":"Merzah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0078-3706","authenticated-orcid":false,"given":"Ivan","family":"Sola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8850-0960","authenticated-orcid":false,"given":"Gerard","family":"Urr\u00fatia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1530-3509","authenticated-orcid":false,"given":"Xavier","family":"Bonfill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,5]]},"reference":[{"issue":"6","key":"3711_CR1","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jamaoncol.2015.2378","volume":"1","author":"HG Prigerson","year":"2015","unstructured":"Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol. 2015;1(6):778\u201384. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2378.","journal-title":"JAMA Oncol"},{"issue":"1","key":"3711_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.7399\/fh.2016.40.1.8918","volume":"40","author":"P Taberner Bonastre","year":"2016","unstructured":"Taberner Bonastre P, Taberner Bonastre MT, Soler Company E, Perez-Serrano Lainosa MD. Chemotherapy near the end of life; assessment of the clinical practise in onco-hematological in adult patients. Farm Hosp. 2016;40(1):14\u201324. https:\/\/doi.org\/10.7399\/fh.2016.40.1.8918.","journal-title":"Farm Hosp"},{"key":"3711_CR3","doi-asserted-by":"publisher","DOI":"10.1159\/000500783","author":"A Vallard","year":"2019","unstructured":"Vallard A, Morisson S, Tinquaut F, Chauvin F, Oriol M, Chapelle C, et al. Drug management in end-of-life hospitalized palliative care cancer patients: the RHESO cohort study. Oncology. 2019. https:\/\/doi.org\/10.1159\/000500783.","journal-title":"Oncology"},{"issue":"4","key":"3711_CR4","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00520-013-2049-3","volume":"22","author":"TL Deshields","year":"2014","unstructured":"Deshields TL, Potter P, Olsen S, Liu J. The persistence of symptom burden: symptom experience and quality of life of cancer patients across 1 year. Support Care Cancer. 2014;22(4):1089\u201396. https:\/\/doi.org\/10.1007\/s00520-013-2049-3.","journal-title":"Support Care Cancer"},{"issue":"6","key":"3711_CR5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.suponc.2011.06.003","volume":"9","author":"TL Deshields","year":"2011","unstructured":"Deshields TL, Potter P, Olsen S, Liu J, Dye L. Documenting the symptom experience of cancer patients. J Support Oncol. 2011;9(6):216\u201323. https:\/\/doi.org\/10.1016\/j.suponc.2011.06.003.","journal-title":"J Support Oncol"},{"issue":"5","key":"3711_CR6","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1089\/jpm.2006.0259","volume":"10","author":"N Fadul","year":"2007","unstructured":"Fadul N, Elsayem A, Palmer JL, Zhang T, Braiteh F, Bruera E. Predictors of access to palliative care services among patients who died at a Comprehensive Cancer Center. J Palliat Med. 2007;10(5):1146\u201352. https:\/\/doi.org\/10.1089\/jpm.2006.0259.","journal-title":"J Palliat Med"},{"issue":"1","key":"3711_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jpainsymman.2013.02.021","volume":"47","author":"D Hui","year":"2014","unstructured":"Hui D, Nooruddin Z, Didwaniya N, Dev R, De La Cruz M, Kim SH, et al. Concepts and definitions for \u201cactively dying\u201d, \u201cend of life\u201d, \u201cterminally ill\u201d, \u201cterminal care\u201d, and \u201ctransition of care\u201d: a systematic review. J Pain Symptom Manage. 2014;47(1):77\u201389. https:\/\/doi.org\/10.1016\/j.jpainsymman.2013.02.021.","journal-title":"J Pain Symptom Manage"},{"issue":"10","key":"3711_CR8","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/s41416-018-0070-5","volume":"118","author":"MN Verkissen","year":"2018","unstructured":"Verkissen MN, Houttekier D, Cohen J, Schots R, Chambaere K, Deliens L. End-of-life decision-making across cancer types: results from a nationwide retrospective survey among treating physicians. Br J Cancer. 2018;118(10):1369\u201376. https:\/\/doi.org\/10.1038\/s41416-018-0070-5.","journal-title":"Br J Cancer"},{"key":"3711_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2020-002453","author":"SY Yang","year":"2020","unstructured":"Yang SY, Park SK, Kang HR, Kim HL, Lee EK, Kwon SH. Haematological cancer versus solid tumour end-of-life care: a longitudinal data analysis. BMJ Support Palliat Care. 2020. https:\/\/doi.org\/10.1136\/bmjspcare-2020-002453.","journal-title":"BMJ Support Palliat Care"},{"issue":"8","key":"3711_CR10","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1089\/jpm.2010.0522","volume":"14","author":"AM Saito","year":"2011","unstructured":"Saito AM, Landrum MB, Neville BA, Ayanian JZ, Weeks JC, Earle CC. Hospice care and survival among elderly patients with lung cancer. J Palliat Med. 2011;14(8):929\u201339. https:\/\/doi.org\/10.1089\/jpm.2010.0522.","journal-title":"J Palliat Med"},{"issue":"19","key":"3711_CR11","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1002\/cncr.25217","volume":"116","author":"AA Wright","year":"2010","unstructured":"Wright AA, Mack JW, Kritek PA, Balboni TA, Massaro AF, Matulonis UA, et al. Influence of patients\u2019 preferences and treatment site on cancer patients\u2019 end-of-life care. Cancer. 2010;116(19):4656\u201363. https:\/\/doi.org\/10.1002\/cncr.25217.","journal-title":"Cancer"},{"key":"3711_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g1219","volume":"348","author":"AA Wright","year":"2014","unstructured":"Wright AA, Zhang B, Keating NL, Weeks JC, Prigerson HG. Associations between palliative chemotherapy and adult cancer patients\u2019 end of life care and place of death: prospective cohort study. BMJ. 2014;348: g1219. https:\/\/doi.org\/10.1136\/bmj.g1219.","journal-title":"BMJ"},{"issue":"2","key":"3711_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/1049909113512412","volume":"32","author":"BH Cheng","year":"2015","unstructured":"Cheng BH, Sham MM, Chan KY, Li CW, Au HY. Intensive palliative care for patients with hematological cancer dying in hospice: analysis of the level of medical care in the final week of life. Am J Hosp Palliat Care. 2015;32(2):221\u20135. https:\/\/doi.org\/10.1177\/1049909113512412.","journal-title":"Am J Hosp Palliat Care"},{"issue":"18","key":"3711_CR14","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1002\/cncr.29485","volume":"121","author":"MC Cheung","year":"2015","unstructured":"Cheung MC, Earle CC, Rangrej J, Ho TH, Liu N, Barbera L, et al. Impact of aggressive management and palliative care on cancer costs in the final month of life. Cancer. 2015;121(18):3307\u201315. https:\/\/doi.org\/10.1002\/cncr.29485.","journal-title":"Cancer"},{"issue":"9","key":"3711_CR15","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00520-009-0577-7","volume":"17","author":"WY Cheung","year":"2009","unstructured":"Cheung WY, Le LW, Zimmermann C. Symptom clusters in patients with advanced cancers. Support Care Cancer. 2009;17(9):1223\u201330. https:\/\/doi.org\/10.1007\/s00520-009-0577-7.","journal-title":"Support Care Cancer"},{"issue":"23","key":"3711_CR16","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1200\/JCO.2007.15.8253","volume":"26","author":"CC Earle","year":"2008","unstructured":"Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of cancer care near the end of life: Is it a quality-of-care issue? J Clin Oncol. 2008;26(23):3860\u20136. https:\/\/doi.org\/10.1200\/JCO.2007.15.8253.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3711_CR17","doi-asserted-by":"publisher","first-page":"pkz021","DOI":"10.1093\/jncics\/pkz021","volume":"3","author":"HM Sineshaw","year":"2019","unstructured":"Sineshaw HM, Jemal A, Ng K, Osarogiagbon RU, Robin Yabroff K, Ruddy KJ, et al. Treatment patterns among de novo metastatic cancer patients who died within 1 month of diagnosis. JNCI Cancer Spectr. 2019;3(2):pkz021. https:\/\/doi.org\/10.1093\/jncics\/pkz021.","journal-title":"JNCI Cancer Spectr"},{"issue":"4","key":"3711_CR18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1634\/theoncologist.2012-0279","volume":"18","author":"SY Zafar","year":"2013","unstructured":"Zafar SY, Peppercorn JM, Schrag D, Taylor DH, Goetzinger AM, Zhong X, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient\u2019s experience. Oncologist. 2013;18(4):381\u201390. https:\/\/doi.org\/10.1634\/theoncologist.2012-0279.","journal-title":"Oncologist"},{"issue":"1","key":"3711_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11864-022-01044-1","volume":"24","author":"D Hui","year":"2023","unstructured":"Hui D, Paiva BSR, Paiva CE. Personalizing the setting of palliative care delivery for patients with advanced cancer: \u201ccare anywhere, anytime.\u201d Curr Treat Options Oncol. 2023;24(1):1\u201311. https:\/\/doi.org\/10.1007\/s11864-022-01044-1.","journal-title":"Curr Treat Options Oncol"},{"issue":"7","key":"3711_CR20","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s00520-024-08598-w","volume":"32","author":"A Taylor","year":"2024","unstructured":"Taylor A, Davies A. The role of specialist palliative care in individuals \u201cliving beyond cancer\u201d: a narrative review of the literature. Support Care Cancer. 2024;32(7):414. https:\/\/doi.org\/10.1007\/s00520-024-08598-w.","journal-title":"Support Care Cancer"},{"issue":"1","key":"3711_CR21","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s12094-023-03234-1","volume":"26","author":"E Szigethy","year":"2023","unstructured":"Szigethy E, Dorantes R, Sugranes M, Madera M, Sola I, Urrutia G, et al. Frequency of anticancer drug use at the end of life: a scoping review. Clin Transl Oncol. 2023;26(1):178\u201389. https:\/\/doi.org\/10.1007\/s12094-023-03234-1.","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"3711_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1759-7714.2012.00148.x","volume":"4","author":"D Yang","year":"2013","unstructured":"Yang D, Qiu M, Zou LQ, Zhang W, Jiang Y, Zhang DY, et al. The role of palliative chemotherapy for terminally ill patients with advanced NSCLC. Thorac Cancer. 2013;4(2):153\u201360. https:\/\/doi.org\/10.1111\/j.1759-7714.2012.00148.x.","journal-title":"Thorac Cancer"},{"issue":"7","key":"3711_CR23","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1007\/s00520-020-05964-2","volume":"29","author":"AJ Davidoff","year":"2021","unstructured":"Davidoff AJ, Canavan ME, Prsic E, Saphire M, Wang SY, Presley CJ. End-of-life patterns of symptom management and cancer-directed care among Medicare beneficiaries with lung cancer: a claims-based analysis. Support Care Cancer. 2021;29(7):3921\u201332. https:\/\/doi.org\/10.1007\/s00520-020-05964-2.","journal-title":"Support Care Cancer"},{"issue":"5","key":"3711_CR24","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1177\/1753465816660925","volume":"10","author":"RB Lim","year":"2016","unstructured":"Lim RB. End-of-life care in patients with advanced lung cancer. Ther Adv Respir Dis. 2016;10(5):455\u201367. https:\/\/doi.org\/10.1177\/1753465816660925.","journal-title":"Ther Adv Respir Dis"},{"issue":"5","key":"3711_CR25","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/jjco\/hyaa259","volume":"51","author":"N Awano","year":"2021","unstructured":"Awano N, Izumo T, Inomata M, Kuse N, Tone M, Takada K, et al. Medical costs of Japanese lung cancer patients during end-of-life care. Jpn J Clin Oncol. 2021;51(5):769\u201377. https:\/\/doi.org\/10.1093\/jjco\/hyaa259.","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"3711_CR26","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.3390\/curroncol28050286","volume":"28","author":"CL Goldie","year":"2021","unstructured":"Goldie CL, Nguyen P, Robinson AG, Goldie CE, Kircher CE, Hanna TP. Quality of end-of-life care for people with advanced non-small cell lung cancer in Ontario: a population-based study. Curr Oncol. 2021;28(5):3297\u2013315. https:\/\/doi.org\/10.3390\/curroncol28050286.","journal-title":"Curr Oncol"},{"issue":"1","key":"3711_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/10499091221091745","volume":"40","author":"TW Lycan Jr","year":"2023","unstructured":"Lycan TW Jr, Buckenheimer A, Ruiz J, Russell G, Dothard AS, Ahmed T, et al. Team-based hospice referrals: a potential quality metric for lung cancer in the immunotherapy era. Am J Hosp Palliat Care. 2023;40(1):10\u20137. https:\/\/doi.org\/10.1177\/10499091221091745.","journal-title":"Am J Hosp Palliat Care"},{"issue":"1","key":"3711_CR28","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12885-021-07992-5","volume":"21","author":"K Oselin","year":"2021","unstructured":"Oselin K, Pisarev H, Ilau K, Kiivet RA. Intensity of end-of-life health care and mortality after systemic anti-cancer treatment in patients with advanced lung cancer. BMC Cancer. 2021;21(1):274. https:\/\/doi.org\/10.1186\/s12885-021-07992-5.","journal-title":"BMC Cancer"},{"key":"3711_CR29","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jclinepi.2020.10.009","volume":"130","author":"H Khalil","year":"2021","unstructured":"Khalil H, Peters MD, Tricco AC, Pollock D, Alexander L, McInerney P, et al. Conducting high quality scoping reviews-challenges and solutions. J Clin Epidemiol. 2021;130:156\u201360. https:\/\/doi.org\/10.1016\/j.jclinepi.2020.10.009.","journal-title":"J Clin Epidemiol"},{"key":"3711_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jclinepi.2015.12.011","volume":"73","author":"AC Tricco","year":"2016","unstructured":"Tricco AC, Antony J, Soobiah C, Kastner M, MacDonald H, Cogo E, et al. Knowledge synthesis methods for integrating qualitative and quantitative data: a scoping review reveals poor operationalization of the methodological steps. J Clin Epidemiol. 2016;73:29\u201335. https:\/\/doi.org\/10.1016\/j.jclinepi.2015.12.011.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"3711_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13643-023-02178-5","volume":"12","author":"F Campbell","year":"2023","unstructured":"Campbell F, Tricco AC, Munn Z, Pollock D, Saran A, Sutton A, et al. Mapping reviews, scoping reviews, and evidence and gap maps (EGMs): the same but different- the \u201cbig picture\u201d review family. Syst Rev. 2023;12(1):45. https:\/\/doi.org\/10.1186\/s13643-023-02178-5.","journal-title":"Syst Rev"},{"key":"3711_CR32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.socscimed.2014.12.007","volume":"131","author":"C Davis","year":"2015","unstructured":"Davis C. Drugs, cancer and end-of-life care: a case study of pharmaceuticalization? Soc Sci Med. 2015;131:207\u201314. https:\/\/doi.org\/10.1016\/j.socscimed.2014.12.007.","journal-title":"Soc Sci Med"},{"issue":"7","key":"3711_CR33","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373. https:\/\/doi.org\/10.7326\/M18-0850.","journal-title":"Ann Intern Med"},{"issue":"12","key":"3711_CR34","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/j.jtho.2020.09.005","volume":"15","author":"T John","year":"2020","unstructured":"John T, Cooper WA, Wright G, Siva S, Solomon B, Marshall HM, et al. Lung cancer in Australia. J Thorac Oncol. 2020;15(12):1809\u201314. https:\/\/doi.org\/10.1016\/j.jtho.2020.09.005.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"3711_CR35","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.21037\/apm-20-1845","volume":"10","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Chen ML, Liu MH, Cheng WW. Chemotherapy and targeted therapy near the end of life affects aggressiveness of palliative care. Ann Palliat Med. 2021;10(3):2917\u201325. https:\/\/doi.org\/10.21037\/apm-20-1845.","journal-title":"Ann Palliat Med"},{"issue":"7","key":"3711_CR36","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s00520-013-1753-3","volume":"21","author":"SC Kao","year":"2013","unstructured":"Kao SC, Van Zandwijk N, Corte P, Clarke C, Clarke S, Vardy J. Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma. Support Care Cancer. 2013;21(7):1879\u201384. https:\/\/doi.org\/10.1007\/s00520-013-1753-3.","journal-title":"Support Care Cancer"},{"issue":"11","key":"3711_CR37","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/annonc\/mdq778","volume":"22","author":"U Nappa","year":"2011","unstructured":"Nappa U, Lindqvist O, Rasmussen BH, Axelsson B. Palliative chemotherapy during the last month of life. Ann Oncol. 2011;22(11):2375\u201380. https:\/\/doi.org\/10.1093\/annonc\/mdq778.","journal-title":"Ann Oncol"},{"issue":"2","key":"3711_CR38","first-page":"1015","volume":"34","author":"C Nieder","year":"2014","unstructured":"Nieder C, Tollali T, Dalhaug A, Haukland E, Aandahl G, Pawinski A, et al. Active anticancer treatment during the final month of life in patients with non-small cell lung cancer. Anticancer Res. 2014;34(2):1015\u201320.","journal-title":"Anticancer Res"},{"issue":"8","key":"3711_CR39","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00432-018-2673-x","volume":"144","author":"Y Zhu","year":"2018","unstructured":"Zhu Y, Tang K, Zhao F, Zang Y, Wang X, Li Z, et al. End-of-life chemotherapy is associated with poor survival and aggressive care in patients with small cell lung cancer. J Cancer Res Clin Oncol. 2018;144(8):1591\u20139. https:\/\/doi.org\/10.1007\/s00432-018-2673-x.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"3711_CR40","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1634\/theoncologist.11-10-1095","volume":"11","author":"JR Murillo Jr","year":"2006","unstructured":"Murillo JR Jr, Koeller J. Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. Oncologist. 2006;11(10):1095\u20139. https:\/\/doi.org\/10.1634\/theoncologist.11-10-1095.","journal-title":"Oncologist"},{"issue":"11","key":"3711_CR41","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1200\/JCO.2005.07.799","volume":"23","author":"W Pao","year":"2005","unstructured":"Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol. 2005;23(11):2556\u201368. https:\/\/doi.org\/10.1200\/JCO.2005.07.799.","journal-title":"J Clin Oncol"},{"key":"3711_CR42","unstructured":"NCCN. Clinical practice guidelines in oncology: non-small cell lung cancer\u2014version 3.2023. 2023."},{"issue":"Suppl 4","key":"3711_CR43","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv192\u2013237. https:\/\/doi.org\/10.1093\/annonc\/mdy275.","journal-title":"Ann Oncol"},{"issue":"4","key":"3711_CR44","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1136\/bmjspcare-2019-001770","volume":"9","author":"O Bylicki","year":"2019","unstructured":"Bylicki O, Didier M, Riviere F, Margery J, Grassin F, Chouaid C. Lung cancer and end-of-life care: a systematic review and thematic synthesis of aggressive inpatient care. BMJ Support Palliat Care. 2019;9(4):413\u201324. https:\/\/doi.org\/10.1136\/bmjspcare-2019-001770.","journal-title":"BMJ Support Palliat Care"},{"issue":"2","key":"3711_CR45","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jpainsymman.2013.03.021","volume":"47","author":"W Hu","year":"2014","unstructured":"Hu W, Yasui Y, White J, Winget M. Aggressiveness of end-of-life care for patients with colorectal cancer in Salberta, Canada: 2006\u20132009. J Pain Symptom Manage. 2014;47(2):231\u201344. https:\/\/doi.org\/10.1016\/j.jpainsymman.2013.03.021.","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"3711_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11606-007-0422-y","volume":"23","author":"NL Keating","year":"2008","unstructured":"Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Care in the months before death and hospice enrollment among older women with advanced breast cancer. J Gen Intern Med. 2008;23(1):11\u20138. https:\/\/doi.org\/10.1007\/s11606-007-0422-y.","journal-title":"J Gen Intern Med"},{"issue":"4","key":"3711_CR47","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/JCO.2003.06.142","volume":"21","author":"EP McCarthy","year":"2003","unstructured":"McCarthy EP, Burns RB, Davis RB, Phillips RS. Barriers to hospice care among older patients dying with lung and colorectal cancer. J Clin Oncol. 2003;21(4):728\u201335. https:\/\/doi.org\/10.1200\/JCO.2003.06.142.","journal-title":"J Clin Oncol"},{"issue":"21","key":"3711_CR48","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.1002\/cncr.26115","volume":"117","author":"KM Sheffield","year":"2011","unstructured":"Sheffield KM, Boyd CA, Benarroch-Gampel J, Kuo YF, Cooksley CD, Riall TS. End-of-life care in Medicare beneficiaries dying with pancreatic cancer. Cancer. 2011;117(21):5003\u201312. https:\/\/doi.org\/10.1002\/cncr.26115.","journal-title":"Cancer"},{"issue":"7","key":"3711_CR49","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s00520-018-4063-y","volume":"26","author":"J Walter","year":"2018","unstructured":"Walter J, Tufman A, Leidl R, Holle R, Schwarzkopf L. Rural versus urban differences in end-of-life care for lung cancer patients in Germany. Support Care Cancer. 2018;26(7):2275\u201383. https:\/\/doi.org\/10.1007\/s00520-018-4063-y.","journal-title":"Support Care Cancer"},{"key":"3711_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e4296","volume":"344","author":"H Llewelyn","year":"2012","unstructured":"Llewelyn H. Evidenced based practice should reduce overdiagnosis and overtreatment. BMJ. 2012;344: e4296. https:\/\/doi.org\/10.1136\/bmj.e4296.","journal-title":"BMJ"},{"issue":"1","key":"3711_CR51","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1024\/0040-5930\/a001328","volume":"79","author":"WD Ludwig","year":"2022","unstructured":"Ludwig WD, Schildmann J, Gockel M. Overtreatment at the end of life in oncology. Ther Umsch. 2022;79(1):53\u201360. https:\/\/doi.org\/10.1024\/0040-5930\/a001328.","journal-title":"Ther Umsch"},{"issue":"19","key":"3711_CR52","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1200\/JCO.24.00542","volume":"42","author":"JJ Sanders","year":"2024","unstructured":"Sanders JJ, Temin S, Ghoshal A, Alesi ER, Ali ZV, Chauhan C, et al. Palliative care for patients with cancer: ASCO guideline update. J Clin Oncol. 2024;42(19):2336\u201357. https:\/\/doi.org\/10.1200\/JCO.24.00542.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3711_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101195","volume":"8","author":"P Stone","year":"2023","unstructured":"Stone P, Buckle P, Dolan R, Feliu J, Hui D, Laird BJA, et al. Prognostic evaluation in patients with advanced cancer in the last months of life: ESMO clinical practice guideline. ESMO Open. 2023;8(2): 101195. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101195.","journal-title":"ESMO Open"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03711-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03711-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03711-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T06:03:36Z","timestamp":1745647416000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03711-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,5]]},"references-count":53,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["3711"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03711-1","relation":{},"ISSN":["1699-3055"],"issn-type":[{"type":"electronic","value":"1699-3055"}],"subject":[],"published":{"date-parts":[[2024,10,5]]},"assertion":[{"value":"3 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}